Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “breast cancer”

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)Recruiting
NCT06902311Phase 2Updated Sep 3, 2026
Sponsor: UNC Lineberger Comprehensive Cancer Center
Breast Cancer · Early-stage Breast Cancer · Ductal Carcinoma in Situ · DCIS
United States
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruiting
NCT06649331Phase 2Updated Sep 3, 2026
Sponsor: Fudan University
Advanced Breast Cancer · Metastatic Breast Cancer · Triple Negative Breast Cancer (TNBC) · HER2-negative Breast Cancer
China
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive Not Recruiting
NCT03820830Phase 3Updated Sep 3, 2026
Sponsor: ETOP IBCSG Partners Foundation
Breast Cancer Recurrent
Austria, France, Hungary, Italy, Spain +1 more
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast CancerCompleted
NCT06827132N/AUpdated Sep 3, 2026
Sponsor: AstraZeneca
Lung Cancer · Breast Cancer
Brazil, Kenya
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingRecruiting
NCT04981119N/AUpdated Sep 3, 2026
Sponsor: A2 Biotherapeutics Inc.
Solid Tumor, Adult · Colorectal Cancer · Non Small Cell Lung Cancer · Pancreatic Cancer
United States
Dissemination of BREASTChoice AIM1-BRecruiting
NCT07396766NAUpdated Sep 3, 2026
Sponsor: UNC Lineberger Comprehensive Cancer Center
Breast Cancer · Breast Neoplasms
United States
Trial of Trastuzumab Deruxtecan in Previously Treated HER2Recruiting
NCT06750484Phase 2Updated Sep 3, 2026
Sponsor: Yale University
Breast Cancer Metastatic
United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruiting
NCT04802759Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
United States, Australia, Israel, South Korea, Spain
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsActive Not Recruiting
NCT06337084Phase 1Updated Sep 3, 2026
Sponsor: Monopar Therapeutics
Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma · Triple-negative Breast Cancer
Australia
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Recruiting
NCT06065748Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
United States, Argentina, Australia, Austria, Belgium +32 more
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast CancerActive Not Recruiting
NCT06813053NAUpdated Sep 3, 2026
Sponsor: University of Colorado, Denver
Breast Cancer
United States
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting
NCT06966700Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +34 more
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruiting
NCT07427394Phase 2Updated Sep 3, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, United Kingdom
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruiting
NCT07413939Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
HER2-positive Breast Cancer
United States, Argentina, Australia, Austria, Belgium +20 more
Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.Not Yet Recruiting
NCT07802847Phase 4Updated Sep 3, 2026
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Elderly · Breast Cancer · Lung Cancer · Prostate Cancer
France
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompleted
NCT03674567Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: RAPT Therapeutics, Inc.
Advanced Cancer
United States, Australia, Hong Kong, South Korea, Taiwan +1 more
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize TrialRecruiting
NCT05379153Phase 3Updated Sep 3, 2026
Sponsor: Alliance for Clinical Trials in Oncology
Vaginal Atrophy · Breast Carcinoma
United States
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesRecruiting
NCT07211178N/AUpdated Sep 3, 2026
Sponsor: Tempus AI
Breast Cancer · TNBC - Triple-Negative Breast Cancer · HR Positive/HER-2 Negative Breast Cancer · HER2 + Breast Cancer
United States
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing ChemotherapyActive Not Recruiting
NCT04724499NAUpdated Sep 3, 2026
Sponsor: Dana-Farber Cancer Institute
Breast Cancer · Chemotherapy Effect · Exercise Therapy · Cognitive Change
United States
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +30 more
Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult WomenNot Yet Recruiting
NCT07802054NAUpdated Sep 3, 2026
Sponsor: Ohio State University Comprehensive Cancer Center
Communication · Message Perception · Alcohol · Cancer Prevention
United States
Adjuvant Treatment in Premenopausal Breast CancerRecruiting
NCT06807749N/AUpdated Sep 3, 2026
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Italy
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsActive Not Recruiting
NCT06617169Phase 1Updated Sep 3, 2026
Sponsor: Monopar Therapeutics
Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma · Triple-negative Breast Cancer
Australia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Cardiometabolic Screening ProgramRecruiting
NCT05386719NAUpdated Sep 3, 2026
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer · Early-stage Breast Cancer
United States

Previous page Next page